Xianhai Huang, Robert G. Aslanian

Case Studies in Modern Drug Discovery and Development

Herausgeber: Huang, Xianhai; Aslanian, Robert G

• Gebundenes Buch

Produktbeschreibung

Learn why some drug discovery and development efforts succeed . . . and others fail
Written by international experts in drug discovery and development, this book sets forth carefully researched and analyzed case studies of both successful and failed drug discovery and development efforts, enabling medicinal chemists and pharmaceutical scientists to learn from actual examples. Each case study focuses on a particular drug and therapeutic target, guiding readers through the drug discovery and development process, including drug design rationale, structure-activity relationships, pharmacology, drug metabolism, biology, and clinical studies.
Case Studies in Modern Drug Discovery and Development begins with an introductory chapter that puts into perspective the underlying issues facing the pharmaceutical industry and provides insight into future research opportunities. Next, there are fourteen detailed case studies, examining:
All phases of drug discovery and development from initial idea to commercialization
Some of today's most important and life-saving medications
Drugs designed for different therapeutic areas such as cardiovascular disease, infection, inflammation, cancer, metabolic syndrome, and allergies
Examples of prodrugs and inhaled drugs
Reasons why certain drugs failed to advance to market despite major research investments
Each chapter ends with a list of references leading to the primary literature. There are also plenty of tables and illustrations to help readers fully understand key concepts, processes, and technologies.
Improving the success rate of the drug discovery and development process is paramount to the pharmaceutical industry. With this book as their guide, readers can learn from both successful and unsuccessful efforts in order to apply tested and proven science and technologies that increase the probability of success for new drug discovery and development projects.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Wiley & Sons
• Artikelnr. des Verlages: 14560181000
• 1. Auflage
• Seitenzahl: 480
• Erscheinungstermin: 29. Mai 2012
• Englisch
• Abmessung: 260mm x 183mm x 30mm
• Gewicht: 1015g
• ISBN-13: 9780470601815
• ISBN-10: 0470601817
• Artikelnr.: 34161108

Autorenporträt

Xianhai Huang, PhD, is a Principal Scientist at Merck Research Laboratories. Dr. Huang is the inventor or co-inventor on more than forty patents and patent applications. As a mentor in the Schering-Plough chemistry postdoctoral program, Dr. Huang and his group discovered novel synthetic applications of (diacetoxyiodo) benzene and successfully applied the methodology to the total synthesis of psymberin, an antitumor natural product. Robert G. Aslanian, PhD, is an adjunct professor of chemistry at William Paterson University and was formerly a Senior Director of Medicinal Chemistry with the Schering-Plough Research Institute and Merck Research Laboratories. Dr. Aslanian has over twenty-five years of experience in the pharmaceutical industry. He is co-inventor on thirty-eight U.S. patents and coauthor on sixty-seven scientific articles and reviews.

Inhaltsangabe

Preface xv Contributors xvii Chapter 1 Introduction: Drug Discovery in Difficult Times 1 Malcolm MacCoss Chapter 2 Discovery and Development of The DPP-4 Inhibitor Januvia® (SITA-GLIPTIN) 10 Emma R. Parmee, Ranabir SinhaRoy, Feng Xu, Jeffrey C. Givand, and Lawrence A. Rosen 2.1 Introduction 10 2.2 DPP-4 Inhibition as a Therapy for Type 2 Diabetes: Identification of Key Determinants for Efficacy and Safety 10 2.2.1 Incretin-Based Therapy for T2DM 10 2.2.2 Biological Rationale: DPP-4 is a Key Regulator of Incretin Activity 11 2.2.3 Injectable GLP-1 Mimetics for the Treatment of T2DM 12 2.2.4 DPP-4 Inhibition as Oral Incretin-Based Therapy for T2DM 12 2.2.5 Investigation of DPP-4 Biology: Identification of Candidate Substrates 13 2.2.6 Preclinical Toxicities of In-Licensed DPP-4 Inhibitors 15 2.2.7 Correlation of Preclinical Toxicity with Off-Target Inhibition of Pro-Specific Dipeptidase Activity 16 2.2.8 Identification of Pro-Specific Dipeptidases Differentially Inhibited by the Probiodrug Compounds 17 2.2.9 A Highly Selective DPP-4 Inhibitor is Safe and Well Tolerated in Preclinical Species 19 2.2.10 A Highly Selective DPP-4 Inhibitor Does Not Inhibit T-Cell Proliferation in vitro 19 2.2.11 DPP-4 Inhibitor Selectivity as a Key Parameter for Drug Development 20 2.3 Medicinal Chemistry Program 20 2.3.1 Lead Generation Approaches 20 2.3.2 Cyclohexyl Glycine
-Amino Acid Series of DPP-4 Inhibitors 20 2.3.3 Improving Selectivity of the
-Amino Acid Series 22 2.3.4 Identification and Optimization of the ß-Amino Acid Series 22 2.4 Synthetic and Manufacturing Routes to Sitagliptin 27 2.4.1 Medicinal Chemistry Route to Sitagliptin and Early Modifications 27 2.4.2 An Asymmetric Hydrogenation Manufacturing Route to Sitagliptin 28 2.4.3 A "Greener" Manufacturing Route to Sitagliptin Employing Biocatalytic Transamination 31 2.5 Drug Product Development 33 2.5.1 Overview 33 2.5.2 Composition Development 33 2.5.3 Manufacturing Process Development 33 2.6 Clinical Studies 36 2.6.1 Preclinical PD Studies and Early Clinical Development of Sitagliptin 36 2.6.2 Summary of Phase II/III Clinical Trials 38 2.7 Summary 39 References 39 Chapter 3 Olmesartan Medoxomil: An Angiotensin II Receptor Blocker 45 Hiroaki Yanagisawa, Hiroyuki Koike, and Shin-ichiro Miura 3.1 Background 45 3.1.1 Introduction 45 3.1.2 Prototype of Orally Active ARBs 46 3.2 The Discovery of Olmesartan Medoxomil (Benicar) 47 3.2.1 Lead Generation 47 3.2.2 Lead Optimization 49 3.3 Characteristics of Olmesartan 53 3.4 Binding Sites of Omlersartan to the AT1 Receptor and Its Inverse Agonoist Activity 56 3.4.1 Binding Sites of Olmesartan to the AT1 Receptor 56 3.4.2 Inverse Agonist Activity of Olmesartan 56 3.4.3 Molecular Model of the Interaction between Olmesartan and the AT1 Receptor 57 3.5 Practical Preparation of Olmesartan Medoxomil 58 3.6 Preclinical Studies 58 3.6.1 AT1 Receptor Blocking Action 58 3.6.2 Inhibition of Ang II-Induced Vascular Contraction 59 3.6.3 Inhibition of the Pressor Response to Ang II 60 3.6.4 Blood Pressure Lowering Effects 60 3.6.5 Organ Protection 61 3.7 Clinical Studies 62 3.7.1 Antihypertensive Efficacy and Safety 62 3.7.2 Organ Protection 63 3.8 Conclusion 63 References 64 Chapter 4 Discovery of Heterocyclic Phosphonic Acids as Novelampmimics That Are Potent and Selective Fructose-1,6-Bisphosphatase Inhibitors and Elicit Potent Glucose-Lowering Effects in Diabetic Animals and Humans 67 Qun Dang and Mark D. Erion 4.1 Introduction 67 4.2 The Discovery of MB06322 69 4.2.1 Research Operation Plan 69 4.2.2 Discovery of Nonnucleotide AMP Mimics as FBPase Inhibitors 69 4.2.3 Discovery of Benzimidazole Phosphonic Acids as FBPase Inhibitors 74 4.2.4 Discovery of Thiazole Phosphonic Acids as Potent and Selective FBPase Inhibitors 77 4.2.5 The Discovery of MB06322 Through Prodrug Strategy 80 4.3 Pharmacokinetic Studies of MB06322 82 4.4 Synthetic Routes to MB06322 83 4.5 Clinical Studies of MB06322 83 4.5.1 Efficacy Study of Thiazole 12.6 in Rodent Models of T2DM 83 4.5.2 Phase I/II Clinical Studies 84 4.6 Summary 84 References 85 Chapter 5 Setting The Paradigm of Targeted Drugs for The Treatment of Cancer: Imatinib and Nilotinib, Therapies for Chronic Myelogenous Leukemia 88 Paul W. Manley and Jurg Zimmermann 5.1 Introduction 88 5.2 Chronic Myelogenous Leukemia (CML) and Early Treatment of the Disease 89 5.3 Imatinib: A Treatment for Chronic Myelogenous Leukemia (CML) 92 5.4 The Need for New Inhibitorts of BCR-ABL1 and Development of Nilotinib 94 5.5 Conclusion 99 References 100 Chapter 6 Amrubicin, A Completely Synthetic 9-Aminoanthracycline for Extensive-Disease Small-Cell Lung Cancer 103 Mitsuharu Hanada 6.1 Introduction 103 6.2 The Discovery of Amrubicin: The First Completely Synthetic Anthracycline 106 6.3 Toxicological Profile of Amrubicin 107 6.4 DNA Topoisomerase II Inhibition and Apoptosis Induction by Amrubicin 110 6.5 Amrubicin Metabolism: The Discovery of Amrubicinol 113 6.5.1 Amrubicinol Functions as an Active Metabolite of Amrubicin 113 6.5.2 Tumor-Selective Metabolism of Amrubicin to Amrubicinol 115 6.6 Improved Usage of Amrubicin 116 6.7 Clinical Trials 118 6.7.1 Clinical Trials of Amrubicin as First-line Therapy in Patients with ED-SCLC 118 6.7.2 Clinical Trials of Amrubicin as Second-Line Therapy in Patients with ED-SCLC 121 6.8 Conclusions 122 References 123 Chapter 7 The Discovery of Dual IGF-1R and IR Inhibitor FQIT for the Treatment of Cancer 127 Meizhong Jin, Elizabeth Buck, and Mark J. Mulvihill 7.1 Biological Rational for Targeting the IGF-1R/IR Pathway for Anti-Cancer Therapy 127 7.2 Discovery of OSI-906 128 7.2.1 Summary of OSI-906 Discovery 128 7.2.2 OSI-906 Clinical Aspects 129 7.3 OSI-906 Back Up Efforts 131 7.4 The Discovery of FQIT 131 7.4.1 Lead Generation Strategy 131 7.4.2 Small Molecule Dual IGF-1R/IR Inhibitor Drug Discovery Cascade 133 7.4.3 Initial Proof-of-Concept Compounds 134 7.4.4 Synthesis of 5,7-Disubstituted Imidazo[5,1-f][1,2,4] Triazines 135 7.4.5 Lead Imidazo[5,1-f][1,2,4] Triazine IGF-1R/IR Inhibitors and Emergence of FQIT 139 7.5 In Vitro Profile of FQIT 140 7.5.1 Cellular and Antiproliferative Effects as a Result of IGF-1R and IR Inhibition 140 7.5.2 Cellular Potency in the Presence of Plasma Proteins 141 7.5.3 In Vitro Metabolism and CYP450 Profile 143 7.6 Pharmacokinetic Properties of FQIT 144 7.6.1 formulation and Salt Study 144 7.6.2 Pharmacokinetics Following Intravenous Administration 144 7.6.3 Pharmacokinetics Following Oral Administration 145 7.7 In Vivo Profile of FQIT 146 7.7.1 In Vivo Pharmacodynamic and PK/PD Correlation 146 7.7.2 In Vivo Efficacy 146 7.8 Safety Assessment and Selectivity Profile of FQIT 148 7.8.1 Effects on Blood Glucose and Insulin Levels 148 7.8.2 Oral Glucose Tolerance Test 148 7.8.3 Ames, Rodent, and Nonrodent Toxicology Studies 149 7.8.4 Selectivity Profile of FQIT 149 7.9 Summary 150 Acknowledgments 151 References 151 Chapter 8 Discovery and Development of Montelukast (Singulair®) 154 Robert N. Young 8.1 Introduction 154 8.2 Drug Development Strategies 158 8.3 LTD4 Antagonist Program 159 8.3.1 Lead Generation and Optimization 159 8.3.2 In Vitro and In Vivo Assays 159 8.4 The Discovery of Montelukast (Singulair®) 160 8.4.1 First-Generation Antagonists (Figure 8.3) 160 8.4.2 Discovery of MK-571 163 8.4.3 Discovery of MK-0679 (29) 168 8.4.4 Discovery of Montelukast (L-706,631, MK-0476, Singulair®) 171 8.5 Synthesis of Montelukast 174 8.5.1 Medicinal Chemistry Synthesis 174 8.5.2 Process Chemistry Synthesis [104, 105] (Schemes 8.5 and 8.6) 176 8.6 ADME Studies with MK-0476 (Montelukast) 179 8.7 Safety Assessment of Montelukast 180 8.8 Clinical Development of Montelukast 180 8.8.1 Human Pharmacokinetics, Safety, and Tolerability 180 8.8.2 Human Pharmacology 181 8.8.3 Phase 2 Studies in Asthma 182 8.8.4 Phase 3 Studies in Asthma 182 8.8.5 Effects of Montelukast on Inflammation 185 8.8.6 Montelukast and Allergic Rhinitis 185 8.9 Summary 185 8.9.1 Impact on Society 185 8.9.2 Lessons Learned 186 8.10 Personal Impact 187 References 188 Chapter 9 Discovery and Development of Maraviroc, A CCR5 Antagonist for the Treatment of HIV Infection 196 Patrick Dorr, Blanda Stammen, and Elna van der Ryst 9.1 Background and Rationale 196 9.2 The Discovery of Maraviroc 199 9.2.1 HTS and Biological Screening to Guide Medicinal Chemistry 199 9.2.2 Hit Optimization 200 9.2.3 Overcoming Binding to hERG 201 9.3 Preclinical Studies 201 9.3.1 Metabolism and Pharmacokinetic Characteristics of Maraviroc 201 9.3.2 Maraviroc Preclinical Pharmacology 202 9.3.3 Preclinical Investigations into HIV Resistance 202 9.3.4 Binding of Maraviroc to CCR5 204 9.4 The Synthesis of Maraviroc 205 9.5 Nonclinical Safety and Toxicity Studies 206 9.5.1 Safety Pharmacology 206 9.5.2 Immuno- and Mechanistic Toxicity 206 9.6 Clinical Development of Maraviroc 207 9.6.1 Phase 1 Studies 207 9.6.2 Phase 2a Studies 209 9.6.3 Phase 2b/3 Studies 210 9.6.4 Development of Resistance to CCR5 Antagonists In Vivo 213 9.7 Summary, Future Directions, and Challenges 214 Acknowledgments 217 References 217 Chapter 10 Discovery of Antimalarial Drug Artemisinin and Beyond 227 Weiwei Mao, Yu Zhang, and Ao Zhang 10.1 Introduction: Natural Products in Drug Discovery 227 10.2 Natural Product Drug Discovery in China 227 10.3 Discovery of Artemisinin: Background, Structural Elucidation and Pharmacological Evaluation 228 10.3.1 Background and Biological Rationale 228 10.3.2 The Discovery of Artemisinin through Nontraditional Drug Discovery Process 229 10.3.3 Structural Determination of Artemisinin 231 10.3.4 Pharmacological Evaluation and Clinical Trial Summary of Artemisinin 231 10.4 The Synthesis of Artemisinin 232 10.4.1 Synthesis of Artemisinin using Photooxidation of Cyclic or Acyclic Enol Ether as the Key Step 233 10.4.2 Synthesis of Artemisinin by Photooxidation of Dihydroarteannuic Acid 236 10.4.3 Synthesis of Artemisinin by Ozonolysis of a Vinylsilane Intermediate 236 10.5 SAR Studies of Structural Derivatives of Artemisinin: The Discovery of Artemether 238 10.5.1 C-10-Derived Artemisinin Analogs 240 10.5.2 C-9 and C-9,10 Double Substituted Analogs 245 10.5.3 C-3 Substituted Analogs 246 10.5.4 C-6 or C-7 Substituted Derivatives 246 10.5.5 C-11-Substituted Analogs 247 10.6 Development of Artemether 248 10.6.1 Profile and Synthesis of Artemether 248 10.6.2 Clinical Studies Aspects of Artemether 249 10.7 Conclusion and Perspective 250 Acknowledgment 250 References 251 Chapter 11 Discovery and Process Development of MK-4965, A Potent Nonnucleoside Reverse Transcriptase Inhibitor 257 Yong-Li Zhong, Thomas J. Tucker, and Jingjun Yin 11.1 Introduction 257 11.2 The Discovery of MK-4965 260 11.2.1 Background Information 260 11.2.2 SAR Studies Leading to the Discovery of MK-4965 262 11.3 Preclinical and Clinical Studies of MK-4965 (19) 266 11.4 Summary of Back-Up SAR Studies of MK-4965 Series 266 11.5 Process Development of MK-4965 (19) 267 11.5.1 Medicinal Chemistry Route 267 11.5.2 Process Development 269 11.6 Conclusion 290 11.6.1 Lessons Learned from the Medicinal Chemistry Effort of MK-4965 Discovery 290 11.6.2 Summary and Lessons Learned from the Process Development of MK-4965 291 Acknowledgments 291 References 291 Chapter 12 Discovery of Boceprevir and Narlaprevir: The First and Second Generation of HCV NS3 Protease Inhibitors 296 Kevin X. Chen and F. George Njoroge 12.1 Introduction 296 12.2 HCV NS3 Protease Inhibitors 298 12.3 Research Operation Plan and Biological Assays 302 12.3.1 Research Operation Plan 302 12.3.2 Enzyme Assay 302 12.3.3 Replicon Assay 302 12.3.4 Measure of Selectivity 303 12.4 Discovery of Boceprevir 303 12.4.1 Initial Lead Generation Through Structure-Based Drug Design 303 12.4.2 SAR Studies Focusing on Truncation, Depeptization, and Macrocyclisation 304 12.4.3 Individual Amino Acid Residue Modifications 307 12.4.4 Correlations Between P1, P3, and P3 Capping: The Identification of Boceprevir 315 12.5 Profile of Boceprevir 317 12.5.1 In Vitro Characterization of Boceprevir 317 12.5.2 Pharmacokinetics of Boceprevir 317 12.5.3 The Interaction of Boceprevir with NS3 Protease 318 12.6 Clinical Development and Approval of Boceprevir 319 12.7 Synthesis of Boceprevir 319 12.8 Discovery of Narlaprevir 322 12.8.1 Criteria for the Back-up Program of Boceprevir 322 12.8.2 SAR Studies 322 12.8.3 Profile of Narlaprevir 326 12.8.4 Clinical Development Aspects of Narlaprevir 327 12.8.5 Synthesis of Narlaprevir 327 12.9 Summary 329 References 330 Chapter 13 The Discoveryofsamsca® (Tolvaptan): Thefirst Oral Nonpeptide Vasopressin Receptor Antagonist 336 Kazumi Kondo and Yoshitaka Yamamura 13.1 Background Information about the Disease 336 13.2 Biological Rational 337 13.3 Lead Generation Strategies: The Discovery of Mozavaptan 338 13.4 Lead Optimization: From Mozavaptan to Tolvaptan 347 13.5 Pharmacological Profiles of Tolvaptan 350 13.5.1 Antagonistic Affinities of Tolvaptan for AVP Receptors 350 13.5.2 Aquaretic Effect Following a Single Dose in Conscious Rats 352 13.6 Drug Development 353 13.6.1 Synthetic Route of Discovery and Commercial Synthesis [10a] 353 13.6.2 Nonclinical Toxicology 353 13.6.3 Clinical Studies 355 13.7 Summary Focusing on Lessons Learned 356 Acknowledgments 357 References 357 Chapter 14 Silodosin (Urief®, Rapaflo®, Thrupas®, Urorec®, Silodix®): A Selective
1A Adrenoceptor Antagonist for the Treatment of Benign Prostatic Hyperplasia 360 Masaki Yoshida, Imao Mikoshiba, Katsuyoshi Akiyama, and Junzo Kudoh 14.1 Background Information 360 14.1.1 Benign Prostatic Hyperplasia 360 14.1.2
1-Adrenergic Receptors 361 14.2 The Discovery of Silodosin 362 14.2.1 Medicinal Chemistry 362 14.2.2 The Synthesis of Silodosin (Discovery Route) 363 14.2.3 Receptor Binding Studies 365 14.3 Pharmacology of Silodosin 369 14.3.1 Action Against Noradrenalin-Induced Contraction of Lower Urinary Tract Tissue 369 14.3.2 Actions Against Phenylephrine-Induced Increase in Intraurethral Pressure and Blood Pressure 371 14.3.3 Actions Against Intraurethral Pressure Increased by Stimulating Hypogastric Nerve and Blood Pressure in Dogs with Benign Prostatic Hyperplasia 372 14.3.4 Safety Pharmacology 373 14.4 Metabolism of Silodosin 373 14.5 Pharmacokinetics of Silodosin 376 14.5.1 Absorption 376 14.5.2 Organ Distribution 377 14.5.3 Excretion 378 14.6 Toxicology of Silodosin 379 14.7 Clinical Trials 382 14.7.1 Phase I Studies 382 14.7.2 Phase III Randomized, Placebo-Controlled, Double-Blind Study 383 14.7.3 Long-Term Administration Study 385 14.8 Summary: Key Lessons Learned 388 References 389 Chapter 15 Raloxifene: A Selective Estrogen Receptor Modulator (SERM) 392 Jeffrey A. Dodge and Henry U. Bryant 15.1 Introduction: SERMs 392 15.2 The Benzothiophene Scaffold: A New Class of SERMs 394 15.3 Assays for Biological Evaluation of Tissue Selectivity 394 15.4 Benzothiophene Structure Activity 395 15.5 The Synthesis of Raloxifene 401 15.6 SERM Mechanism 402 15.7 Raloxifene Pharmacology 405 15.7.1 Skeletal System 405 15.7.2 Reproductive System-Uterus 407 15.7.3 Reproductive System-Mammary 408 15.7.4 General Safety Profile and Other Pharmacological Considerations 410 15.8 Summary 411 References 411 Appendix I Small Molecule Drug Discovery and Development Paradigm 417 Appendix II Glossary 419 Appendix III Abbreviations 432 Index 443